Jane Street Group LLC Purchases 8,010 Shares of Omeros Co. (NASDAQ:OMER)

Jane Street Group LLC lifted its stake in Omeros Co. (NASDAQ:OMER) by 15.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 58,277 shares of the biopharmaceutical company’s stock after acquiring an additional 8,010 shares during the period. Jane Street Group LLC’s holdings in Omeros were worth $231,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in OMER. Wellington Management Group LLP purchased a new stake in shares of Omeros in the third quarter worth $305,000. State Street Corp increased its holdings in shares of Omeros by 0.3% in the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after buying an additional 3,839 shares during the period. HighTower Advisors LLC increased its holdings in shares of Omeros by 7.2% in the third quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock worth $235,000 after buying an additional 4,000 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Omeros by 130.6% in the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 7,016 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Omeros by 4.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock worth $1,926,000 after buying an additional 18,454 shares during the period. 48.79% of the stock is owned by institutional investors.

Omeros Price Performance

Shares of OMER stock opened at $8.84 on Friday. Omeros Co. has a 1 year low of $2.61 and a 1 year high of $13.60. The firm has a fifty day moving average price of $8.89 and a 200-day moving average price of $5.84. The company has a market cap of $512.28 million, a price-to-earnings ratio of -3.83 and a beta of 2.01.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. D. Boral Capital initiated coverage on Omeros in a research note on Monday, December 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. Rodman & Renshaw started coverage on Omeros in a research report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price target on the stock. StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, RODMAN&RENSHAW upgraded shares of Omeros to a “strong-buy” rating in a report on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $22.50.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.